🌍 Plants reduce contamination risks and require smaller facilities compared to traditional methods.
💡 Technologies allow easy scaling with vertical cultivation, responding quickly to demand changes.
✅ Molecular farming is gaining FDA approval, with examples like plant-based vaccines.
🚀 This approach promises lower costs and a greener footprint in biopharmaceutical production.
Introduction:
The article discusses the emerging field of molecular farming, which utilizes plants to produce therapeutic proteins. This approach offers several advantages over traditional cell-based production systems, highlighting the potential for lower costs and reduced environmental impact.
- Molecular farming employs plants for the production of therapeutic proteins, providing a safer alternative to bacterial and mammalian systems due to lower contamination risks.
- Recent advancements have made it feasible to scale production without the need for larger facilities, utilizing vertical hydroponic systems for cultivation.
- Several plant-derived biopharmaceuticals, including FDA-approved products, have demonstrated the viability of this method, gaining regulatory acceptance.
- The production process for plant-based proteins closely resembles traditional biopharmaceutical manufacturing, particularly in downstream processing.
- PlantForm’s vivoXpress technology exemplifies an innovative approach to efficient and cost-effective biologic drug production, including ongoing projects for cancer biosimilars.
Conclusion:
The growing interest in molecular farming signifies a promising shift towards utilizing plants for biopharmaceutical production, indicative of potential cost savings, sustainability, and regulatory viability. Future directions may involve further advancements in cultivation technology and increased integration of this method within the broader pharmaceutical landscape.
